Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Sanofi Succeeds 4 Boehringer Brands in Japan under Global Asset Swap
July 4, 2017
- Signifor Filed for Cushing’s Disease in Japan: Novartis
July 4, 2017
- FDA Accepts NDA Resubmission for Sunovion’s COPD Med
July 4, 2017
- Evaluate Forecasts CAGR of 3.3% for Japan Market
July 4, 2017
- Delving into Securities Filings - Part 1: 27 Drug Makers’ Workforce Down 0.5% as Major Firms Continue to Shed Jobs
July 4, 2017
- Ex-JPMA Chief Aoki Wants to See Japan’s Gilead, Govt Leadership in Consolidation
July 3, 2017
- Takeda Puts Up 2.75 Billion Yen for Health Programs in Developing Nations
July 3, 2017
- Mirogabalin Hits Primary Endpoint in Post-Herpetic Neuralgia: Daiichi Sankyo
July 3, 2017
- Astellas Files US sNDA for Myrbetriq-Vesicare Combo Use
July 3, 2017
- Kyowa Kirin Launches Japan PIII Trial on Mogamulizumab for HTLV-1-Associated Myelopathy
July 3, 2017
- Nippon Kayaku Prevails in Elplat Damage Suit: High Court
June 30, 2017
- Takeda Files Teva’s Parkinson’s Disease Med in Japan
June 30, 2017
- Weber’s FY2016 Pay Tops 1 Billion Yen: Takeda Securities Filing
June 30, 2017
- Oncolys to Initiate PI Trial of Oncolytic Virus Telomelysin “Shortly” in Japan
June 30, 2017
- Takeda Chairman Hasegawa Officially Steps Aside as Adviser
June 29, 2017
- Eisai Temporarily Rescinds NDA for Halaven in China due to Request for Additional Data
June 29, 2017
- Adcetris Hits Primary Endpoint in PIII Trial for Frontline Advanced Hodgkin’s Lymphoma: Takeda, Seattle Genetics
June 29, 2017
- AbbVie Japan Set to Build Up Organization to Gear Up for Oncology Drug Launches: President
June 28, 2017
- Drug Makers Moving to Outsource “Pharmaceutical Scouting” to Seek Efficiency: Ex-Sanofi Exec
June 28, 2017
- Stivarga OK’ed for 2nd-Line HCC, Oldamin for Gastric Varices, Actemra for Shorter Dose Interval
June 27, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…